Abstract:Background: Teprotumumab, an IGF-1R monoclonal antibody, has shown significant efficacy in treating thyroid eye disease (TED). However, since teprotumumab was launched in 2020 and first approved in the United States, there were limited reports of post-marketing adverse events (AEs). In this study, we aimed to mine and analyze the AEs signals with teprotumumab on the basis of the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to provide instructions in clinical practice concerning adverse reactions and assistance in drug development and import/export into other countries. Methods: All AE reports were obtained from the FAERS database from the first quarter of 2020 to the fourth quarter of 2023. To comprehensively analyze the AEs, we applied four disproportionality analysis algorithms, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms. Results: A total of 687 reports from 200 patients related to administration of teprotumumab were obtained, and 78% of the cases was female. Signal detection of teprotumumab at the system organ class (SOC) level included gastrointestinal disorders, ear and labyrinth disorders, general disorders and administration site conditions, nervous system disorders, and musculoskeletal and connective tissue disorders. AEs that ranked top five at the preferred terms (PTs) level were muscle spasms, fatigue, tinnitus, headache, and deafness. The median time to those AEs onsets was 48 days (interquartile range 19.0-92.0 days) after administering drugs. Additionally, our results indicated the AEs in reproductive system and breast disorders because the prevalence of TED was more common in women. Conclusion: This study identified many AEs associated with teprotumumab and unveiled potential new AE signals. These results can provide valuable evidence for further clinical application of teprotumumab and are important in enhancing clinical medication safety.

Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system

An observational study on the safety of teprotumumab based on FAERS database

Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment

Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease

A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the FDA Adverse Event Reporting System

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database

A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin

A real-world pharmacovigilance study of tafasitamab: data mining of the US food and drug administration adverse event reporting system

Adverse events associated with tezepelumab: a safety analysis of clinical trials and a pharmacovigilance system

Teprotumumab: A Review in Thyroid Eye Disease

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Hearing abnormalities in patients treated with teprotumumab

Data Mining and Safety Analysis of Avatrombopag: a Retrospective Pharmacovigilance Study Based on the US Food and Drug Administration’s Adverse Event Reporting System

Clinical Management, Monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan

A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib

Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system

Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database